Pfizer Inc. is working with a partner in China to make the Covid-19 drug Paxlovid available there starting in the first half of the year, Chief Executive Officer Albert Bourla said in a presentation.
(Bloomberg) — Pfizer Inc. is working with a partner in China to make the Covid-19 drug Paxlovid available there starting in the first half of the year, Chief Executive Officer Albert Bourla said in a presentation.
The partner hasn’t started production but will soon, Bourla said Monday at the JPMorgan Healthcare Conference in San Francisco, without naming the company. He also shot down a Reuters report from last week that said companies are working to make generic versions available in China.
Chinese health officials are working to combat a rampant outbreak of Covid after easing restrictions designed to curb the spread of the virus. Talks between the country and Pfizer to negotiate a lower price for Paxlovid and get it covered under state insurance haven’t panned out, the health authority there said Sunday.
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.